Adrian Gottschalk
Known title: Chief Executive OfficerCIK: 0001828724
Associated companies
Transaction History
| FHTX | ▼ Sell | Gift | 59,208 | $0 | 4/10/2026 | View on chart |
| FHTX | ▼ Sell | Gift | 59,208 | $0 | 4/10/2026 | View on chart |
| FHTX | ▼ Sell | Gift | 47,497 | $0 | 4/9/2026 | View on chart |
| FHTX | ▼ Sell | Gift | 47,497 | $0 | 4/9/2026 | View on chart |
| FHTX | ▼ Sell | Gift | 300,000 | $0 | 4/25/2025 | View on chart |
| FHTX | ▼ Sell | Gift | 300,000 | $0 | 4/25/2025 | View on chart |
| FHTX | ▼ Sell | Gift | 197,906 | $0 | 4/9/2025 | View on chart |
| FHTX | ▼ Sell | Gift | 197,906 | $0 | 4/9/2025 | View on chart |
| FHTX | ▼ Sell | Gift | 63,000 | $0 | 8/17/2023 | View on chart |
| FHTX | ▼ Sell | Gift | 63,000 | $0 | 8/17/2023 | View on chart |
| FHTX | ▼ Sell | Gift | 300,000 | $0 | 5/26/2023 | View on chart |
| FHTX | ▼ Sell | Gift | 300,000 | $0 | 5/26/2023 | View on chart |
| FHTX | ▼ Sell | Gift | 4,371 | $0 | 2/17/2023 | View on chart |
| FHTX | ▼ Sell | Gift | 4,371 | $0 | 2/17/2023 | View on chart |
| FHTX | ▼ Sell | Other | 184,939 | $0 | 2/17/2023 | View on chart |
| FHTX | ▼ Sell | Other | 184,939 | $0 | 2/17/2023 | View on chart |
| FHTX | ▼ Sell | Other | 4,371 | $0 | 10/25/2022 | View on chart |
| FHTX | ▼ Sell | Other | 4,371 | $0 | 10/25/2022 | View on chart |
| FHTX | ▲ Buy | Option Exercise | 40,000 | $22K | 9/16/2022 | View on chart |
| FHTX | ▼ Sell | Gift | 123,479 | $0 | 2/10/2022 | View on chart |
| FHTX | ▼ Sell | Gift | 123,479 | $0 | 2/10/2022 | View on chart |
| FHTX | ▲ Buy | Option Exercise | 23,000 | $12K | 8/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Foghorn and Lilly halt FHD-909 development
Foghorn Therapeutics announced it will not advance the FHD-909 program into the clinical development expansion phase with Lilly. This decision marks a significant setback for the company's pipeline, as it halts progress on a key partnership. The news explains why the stock is trading near its 52-week low, reflecting the impact of this strategic pause on market sentiment.
Foghorn and Lilly halt FHD-909 development. Foghorn Therapeutics announced it will not advance the FHD-909 program into the clinical development expansion phase with Lilly. This decision marks a significant setback for the company's pipeline, as it halts progress on a key partnership. The news explains why the stock is trading near its 52-week low, reflecting the impact of this strategic pause on market sentiment.